These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 36290893)

  • 1. Promising Immune Treatment of Advanced Cutaneous Squamous Cell Carcinoma with Cemiplimab-Real-World Experience in the Global SARS-CoV-2 Pandemic.
    Pabianek M; Lesiak A; Nejc D; Kuncman Ł; Narbutt J; Skibińska M; Ciążyńska M
    Curr Oncol; 2022 Oct; 29(10):7794-7801. PubMed ID: 36290893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma: Real-World Experience in a Monographic Oncology Center.
    Ríos-Viñuela E; Álvarez P; Lavernia J; Serra-Guillén C; Requena C; Bernia E; Diago A; Llombart B; Sanmartín O
    Actas Dermosifiliogr; 2022 Jun; 113(6):T610-T615. PubMed ID: 35525283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma: Real-World Experience in a Monographic Oncology Center.
    Ríos-Viñuela E; Álvarez P; Lavernia J; Serra-Guillén C; Requena C; Bernia E; Diago A; Llombart B; Sanmartín O
    Actas Dermosifiliogr; 2022 Jun; 113(6):610-615. PubMed ID: 35431057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cemiplimab for locally advanced cutaneous squamous cell carcinoma: safety, efficacy, and position in therapy panel.
    Lebas E; Marchal N; Rorive A; Nikkels AF
    Expert Rev Anticancer Ther; 2021 Apr; 21(4):355-363. PubMed ID: 33554680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma.
    Villani A; Ocampo-Garza SS; Potestio L; Fabbrocini G; Ocampo-Candiani J; Ocampo-Garza J; Scalvenzi M
    Expert Opin Drug Saf; 2022 Jan; 21(1):21-29. PubMed ID: 34644510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of CCL-20 and CXCL-8 genes enhances tumor escape and resistance to cemiplimab, a programmed cell death protein-1 (PD-1) inhibitor, in patients with locally advanced and metastatic cutaneous squamous cell carcinoma.
    De Falco V; Napolitano S; Franco R; Zito Marino F; Formisano L; Esposito D; Suarato G; Napolitano R; Esposito A; Caraglia F; Giugliano MC; Cioli E; Famiglietti V; Bianco R; Argenziano G; Ronchi A; Ciardiello D; Nardone V; D'Ippolito E; Del Tufo S; Ciardiello F; Troiani T
    Oncoimmunology; 2024; 13(1):2388315. PubMed ID: 39206096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CASE (CemiplimAb-rwlc Survivorship and Epidemiology) study in advanced cutaneous squamous cell carcinoma.
    Migden MR; Chandra S; Rabinowits G; Chen CI; Desai J; Seluzhytsky A; Sasane M; Campanelli B; Chen Z; Freeman ML; Ibrahim SF; Khushalani NI; Andria M; Ruiz E
    Future Oncol; 2020 Feb; 16(4):11-19. PubMed ID: 31951149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Previous radiotherapy increases the efficacy of cemiplimab in the treatment of locally advanced and metastatic cutaneous squamous cell carcinoma: A retrospective analysis.
    Nardone V; Napolitano S; Gagliardi F; Esposito A; Caraglia F; Briatico G; Scharf C; Ronchi A; D'Onofrio I; D'Ippolito E; Russo A; Belfiore MP; Franco R; Argenziano G; Ciardiello F; Reginelli A; Cappabianca S; Troiani T
    J Am Acad Dermatol; 2024 Oct; 91(4):678-683. PubMed ID: 38885840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cemiplimab in advanced cutaneous squamous cell carcinoma.
    Naik PP
    Dermatol Ther; 2021 Nov; 34(6):e15184. PubMed ID: 34716727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial.
    Migden MR; Khushalani NI; Chang ALS; Lewis KD; Schmults CD; Hernandez-Aya L; Meier F; Schadendorf D; Guminski A; Hauschild A; Wong DJ; Daniels GA; Berking C; Jankovic V; Stankevich E; Booth J; Li S; Weinreich DM; Yancopoulos GD; Lowy I; Fury MG; Rischin D
    Lancet Oncol; 2020 Feb; 21(2):294-305. PubMed ID: 31952975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Cemiplimab as Adjuvant or Neoadjuvant Therapy in the Treatment of Cutaneous Squamous Cell Carcinoma.
    Hiller A; Oxford M; Kulkarni P; Fornadley J; Lo A; Sivik J; Drabick J; Vakharia K
    Ann Plast Surg; 2024 Apr; 92(4S Suppl 2):S129-S131. PubMed ID: 38556660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Locally advanced and metastatic cutaneous squamous cell carcinoma treated with cemiplimab].
    Vanhakendover L; Lebas E; Libon F; Wauters O; Dezfoulian B; Marchal N; Rorive A; Piret P; Quatresooz P; Jacquemin D; Nikkels AF
    Rev Med Liege; 2019 Jul; 74(7-8):436-440. PubMed ID: 31373461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cemiplimab: A Review in Advanced Cutaneous Squamous Cell Carcinoma.
    Lee A; Duggan S; Deeks ED
    Drugs; 2020 Jun; 80(8):813-819. PubMed ID: 32306208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma.
    Ahmed SR; Petersen E; Patel R; Migden MR
    Expert Rev Clin Pharmacol; 2019 Oct; 12(10):947-951. PubMed ID: 31524530
    [No Abstract]   [Full Text] [Related]  

  • 15. Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma.
    Baggi A; Quaglino P; Rubatto M; Depenni R; Guida M; Ascierto PA; Trojaniello C; Queirolo P; Saponara M; Peris K; Spagnolo F; Bianchi L; De Galitiis F; Potenza MC; Proietti I; Marconcini R; Botticelli A; Barbieri V; Licitra L; Alfieri S; Ficorella C; Cortellini A; Fargnoli MC; Troiani T; Tondulli L; Bossi P
    Eur J Cancer; 2021 Nov; 157():250-258. PubMed ID: 34536948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment.
    Stratigos AJ; Garbe C; Dessinioti C; Lebbe C; Bataille V; Bastholt L; Dreno B; Concetta Fargnoli M; Forsea AM; Frenard C; Harwood CA; Hauschild A; Hoeller C; Kandolf-Sekulovic L; Kaufmann R; Kelleners-Smeets NWJ; Malvehy J; Del Marmol V; Middleton MR; Moreno-Ramirez D; Pellecani G; Peris K; Saiag P; van den Beuken-van Everdingen MHJ; Vieira R; Zalaudek I; Eggermont AMM; Grob JJ;
    Eur J Cancer; 2020 Mar; 128():83-102. PubMed ID: 32113942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cemiplimab for Locally Advanced Cutaneous Squamous Cell Carcinoma: A Case Series of 3 Unique Scenarios.
    Akhtar K; Sravanthi MV; D'Angelo J; Sivapiragasam A
    J Investig Med High Impact Case Rep; 2022; 10():23247096221121408. PubMed ID: 36017984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case Series: Cemiplimab and Nivolumab Immunotherapy as Promising Treatment in Advanced or Metastatic Cutaneous Squamous Cell Carcinoma.
    Lai FY; Clarke R; Cooper P; Stokes J; Calvert P
    Case Rep Oncol; 2023; 16(1):1156-1165. PubMed ID: 37900839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Libtayo
    Gupta AK; Mann A; Vincent K; Abramovits W
    Skinmed; 2024; 22(2):138-143. PubMed ID: 39090000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response of advanced cutaneous squamous cell carcinoma to immunotherapy: case report.
    Ashraf S; Alsharedi M
    Stem Cell Investig; 2021; 8():19. PubMed ID: 34631872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.